Chugai Pharmaceutical Co., Ltd. (Japan) and Taisho Pharmaceutical Release: Eldecalcitol, an Active Vitamin D3 Derivative, Reduces Incidence of New Vertebral Fractures in Osteoporosis Patients in Phase III Clinical Trial

Tokyo, Dec 16, 2008 (JCN Newswire) - Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd. announced today that the active vitamin D3 derivative being co-developed by the two companies for treatment of osteoporosis (generic name: eldecalcitol; Chugai development code: ED-71, Taisho development code: CT-081) significantly reduced the incidence of new vertebral fractures in osteoporosis patients in a randomized, double-blind, comparative trial. Detailed study results will be published in a medical journal and announced at a medical conference.